Cardiovascular inflammation is reduced with methotrexate in diabetes

Molecular and Cellular Biochemistry

Volumn 432, Issue 1-2, 2017, Pages 159-167

  Quan, Adrian ^a   Pan, Yi ^a   Singh, Krishna K ^a,b   Polemidiotis, John ^a   Teoh, Hwee ^a   Leong Poi, Howard ^a,c   Verma, Subodh ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Diabetes; Inflammation; Methotrexate

Indexed keywords

ACETYLCHOLINE; ADIPONECTIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 10; INTERLEUKIN 12P70; INTERLEUKIN 1BETA; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHOTREXATE; SODIUM CHLORIDE; STROMAL CELL DERIVED FACTOR 1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR INFLAMMATION; CLINICAL ASSESSMENT; CONCENTRATION PROCESS; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; THORACIC AORTA; VASODILATATION; WESTERN DIET; ANIMAL; CARDIOVASCULAR DISEASE; DIABETIC COMPLICATION; GENETICS; INFLAMMATION; METABOLISM; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; INFLAMMATION; METHOTREXATE; MICE; MICE, TRANSGENIC;

EID: 85015625622     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-017-3006-0     Document Type: Article

References (48)

1. World Health Organization (2015) Cardiovascular diseases (CVDs). In: Centre M (ed), World Health Organization, Geneva
2. International Diabetes Federation (2015) IDF Diabetes Atlas, 7 ed. In: Federation ID (ed), International Diabetes Federation, Brussels
3. Emerging Risk Factors C, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215–2222. doi:10.1016/S0140-6736(10)60484-9
4. Nwaneri C, Cooper H, Bowen-Jones D (2013) Mortality in type 2 diabetes mellitus: magnitude of the evidence from a systematic review and meta-analysis. Br J Diabetes Vasc Dis 13:192–207
5. N. C. D. Risk Factor Collaboration (2016) Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet doi:10.1016/S0140-6736(16)00618-8
6. World Health Organization (2015) Obesity and overweight. In: Centre M (ed), World Health Organization, Geneva
7. Cardiometabolic Risk Working Group, Executive C, Leiter LA, Fitchett DH, Gilbert RE, Gupta M, Mancini GB, McFarlane PA, Ross R, Teoh H, Verma S, Anand S, Camelon K, Chow CM, Cox JL, Despres JP, Genest J, Harris SB, Lau DC, Lewanczuk R, Liu PP, Lonn EM, McPherson R, Poirier P, Qaadri S, Rabasa-Lhoret R, Rabkin SW, Sharma AM, Steele AW, Stone JA, Tardif JC, Tobe S, Ur E (2011) Cardiometabolic risk in Canada: a detailed analysis and position paper by the cardiometabolic risk working group. Can J Cardiol 27:e1–e33. doi:10.1016/j.cjca.2010.12.054
8. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, McCarren M, Duckworth WC, Emanuele NV and Investigators V (2015) Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 372:2197–2206. doi:10.1056/NEJMoa1414266
9. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA (2008) 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577–1589. doi:10.1056/NEJMoa0806470
10. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE and Investigators E-RO (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373:2117–2128. doi:10.1056/NEJMoa1504720
11. Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsboll T and Investigators S- (2016) Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. doi:10.1056/NEJMoa1607141
12. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, Committee LS and Investigators LT (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311–322. doi:10.1056/NEJMoa1603827
13. Swedberg K, Ryden L (2016) Treatment of diabetes and heart failure: joint forces. Eur Heart J 37:1535–1537. doi:10.1093/eurheartj/ehw039
14. Rajasekeran H, Lytvyn Y, Cherney DZ (2016) Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int 89:524–526. doi:10.1016/j.kint.2015.12.038
15. Drucker DJ (2016) The cardiovascular biology of glucagon-like peptide-1. Cell Metab 24:15–30. doi:10.1016/j.cmet.2016.06.009
16. Everett BM, Pradhan AD, Solomon DH, Paynter N, Macfadyen J, Zaharris E, Gupta M, Clearfield M, Libby P, Hasan AA, Glynn RJ, Ridker PM (2013) Rationale and design of the cardiovascular inflammation reduction trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J 166(199–207):e15. doi:10.1016/j.ahj.2013.03.018
17. Guin A, Chatterjee Adhikari M, Chakraborty S, Sinhamahapatra P, Ghosh A (2013) Effects of disease modifying anti-rheumatic drugs on subclinical atherosclerosis and endothelial dysfunction which has been detected in early rheumatoid arthritis: 1-year follow-up study. Semin Arthritis Rheum 43:48–54. doi:10.1016/j.semarthrit.2012.12.027
18. Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, Ostor AJ, Edwards CJ (2010) The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 49:295–307. doi:10.1093/rheumatology/kep366
19. Micha R, Imamura F, Wyler von Ballmoos M, Solomon DH, Hernan MA, Ridker PM, Mozaffarian D (2011) Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol 108:1362–1370. doi:10.1016/j.amjcard.2011.06.054
20. DeOliveira CC, Acedo SC, Gotardo EM, Carvalho Pde O, Rocha T, Pedrazzoli J, Jr. and Gambero A (2012) Effects of methotrexate on inflammatory alterations induced by obesity: an in vivo and in vitro study. Mol Cell Endocrinol 361: 92–98. doi:10.1016/j.mce.2012.03.016
21. Russo GT, Minutoli L, Bitto A, Altavilla D, Alessi E, Giandalia A, Romeo EL, Stagno MF, Squadrito F, Cucinotta D, Selhub J (2012) Methotrexate increases skeletal muscle GLUT4 expression and improves metabolic control in experimental diabetes. J Nutr Metab 2012:132056. doi:10.1155/2012/132056
22. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee (2013) Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 37:S1–S212
23. Handelsman Y, Bloomgarden ZT, Grunberger G, Umpierrez G, Zimmerman RS, Bailey TS, Blonde L, Bray GA, Cohen AJ, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda OP, Garber AJ, Garvey WT, Henry RR, Hirsch IB, Horton ES, Hurley DL, Jellinger PS, Jovanovic L, Lebovitz HE, LeRoith D, Levy P, McGill JB, Mechanick JI, Mestman JH, Moghissi ES, Orzeck EA, Pessah-Pollack R, Rosenblit PD, Vinik AI, Wyne K, Zangeneh F (2015) American Association of Clinical Endocrinologists and American College of Endocrinology—clinical practice guidelines for developing a diabetes mellitus comprehensive care plan—2015. Endocr Pract 21(Suppl 1):1–87. doi:10.4158/EP15672.GL
24. International Diabetes Federation (2013) IDF Global Guideline for Managing Older People with Type 2 Diabetes. International Diabetes Federation, Brussels
25. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140–149. doi:10.2337/dc14-2441
26. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C (2011) Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 343:d4169. doi:10.1136/bmj.d4169
27. Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT (2008) Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545–2559. doi:10.1056/NEJMoa0802743
28. Zoungas S, Chalmers J, Neal B, Billot L, Li Q, Hirakawa Y, Arima H, Monaghan H, Joshi R, Colagiuri S, Cooper ME, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Lisheng L, Mancia G, Marre M, Matthews DR, Mogensen CE, Perkovic V, Poulter N, Rodgers A, Williams B, MacMahon S, Patel A, Woodward M, Group A-OC (2014) Follow-up of blood-pressure lowering and glucose control in type 2 diabetes. N Engl J Med 371: 1392–1406. doi:10.1056/NEJMoa1407963
29. Rabi DM, Padwal R, Tobe SW, Gilbert RE, Leiter LA, Quinn RR, Khan N, Canadian Hypertensive Education P and Canadian Diabetes A (2013) Risks and benefits of intensive blood pressure lowering in patients with type 2 diabetes. CMAJ 185:963–967. doi:10.1503/cmaj.120112
30. Accord Study Group, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585. doi:10.1056/NEJMoa1001286
31. Accord Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362:1563–1574. doi:10.1056/NEJMoa1001282
32. Cholesterol Treatment Trialists C, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C (2008) Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 371:117–125. doi:10.1016/S0140-6736(08)60104-X
33. Stegman B, Puri R, Cho L, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nissen SE, Nicholls SJ (2014) High-intensity statin therapy alters the natural history of diabetic coronary atherosclerosis: insights from SATURN. Diabetes Care 37:3114–3120. doi:10.2337/dc14-1121
34. Tabas I (2016) 2016 Russell Ross memorial lecture in vascular biology: molecular-cellular mechanisms in the progression of atherosclerosis. Arterioscler Thromb Vasc Biol. doi:10.1161/ATVBAHA.116.308036
35. Libby P (2012) Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 32:2045–2051. doi:10.1161/ATVBAHA.108.179705
36. Donath MY (2016) Multiple benefits of targeting inflammation in the treatment of type 2 diabetes. Diabetologia 59:679–682. doi:10.1007/s00125-016-3873-z
37. Avogaro A, Albiero M, Menegazzo L, de Kreutzenberg S, Fadini GP (2011) Endothelial dysfunction in diabetes: the role of reparatory mechanisms. Diabetes Care 34(Suppl 2):S285–S290. doi:10.2337/dc11-s239
38. Kohlgruber A, Lynch L (2015) Adipose tissue inflammation in the pathogenesis of type 2 diabetes. Curr Diab Rep 15:92. doi:10.1007/s11892-015-0670-x
39. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM (2001) C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 286:327–334
40. Zeadin MG, Petlura CI, Werstuck GH (2013) Molecular mechanisms linking diabetes to the accelerated development of atherosclerosis. Can J Diabetes 37:345–350. doi:10.1016/j.jcjd.2013.06.001
41. Libby P (2001) Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104:365–372
42. Hansson GK, Hermansson A (2011) The immune system in atherosclerosis. Nat Immunol 12:204–212. doi:10.1038/ni.2001
43. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O’Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625–639. doi:10.1002/acr.21641
44. Rho YH, Oeser A, Chung CP, Milne GL and Stein CM (2009) Drugs used in the treatment of rheumatoid arthritis: relationship between current use and cardiovascular risk factors. Arch Drug Inf 2:34–40. doi:10.1111/j.1753-5174.2009.00019.x
45. Group CI (2016) Cardiovascular Inflammation Reduction Trial (CIRT). Clinicaltrials.gov, December 20, 2016 edn
46. Sung JY, Hong JH, Kang HS, Choi I, Lim SD, Lee JK, Seok JH, Lee JH, Hur GM (2000) Methotrexate suppresses the interleukin-6 induced generation of reactive oxygen species in the synoviocytes of rheumatoid arthritis. Immunopharmacology 47:35–44
47. Johnston A, Gudjonsson JE, Sigmundsdottir H, Ludviksson BR, Valdimarsson H (2005) The anti-inflammatory action of methotrexate is not mediated by lymphocyte apoptosis, but by the suppression of activation and adhesion molecules. Clin Immunol 114:154–163. doi:10.1016/j.clim.2004.09.001
48. Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH (2001) Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 60:729–735